12.68

1.70% -0.13

Immunome Inc (IMNM)

Overview News Price History Option Chain Financials Discussions Forecast

Immunome Inc stock is traded at $12.68, with a volume of 186.79K. It is down -1.70% in the last 24 hours and down -4.39% over the past month. Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which itcan efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious disease, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP) and and IM-4320.

Previous Close:

$12.81

Open:

$12.78

24h Volume:

186.79K

Relative Volume:

0.31

Market Cap:

$789.78M

Revenue:

Net Income/Loss:

$-106.81M

P/E Ratio:

-5.7636

EPS:

-2.2

Net Cash Flow:

$-8.40M

1W Performance:

+3.22%

1M Performance:

-4.39%

6M Performance:

-20.05%

1Y Performance:

+43.91%

1-Day Range:

$12.49

$12.89

1-Week Range:

$11.40

$12.89

52-Week Range:

$6.93

$30.96

Immunome Inc Stock (IMNM) Company Profile

Name

Immunome Inc

Sector

Healthcare (1181)

Industry

Biotechnology (680)

Phone

610-321-3700

Address

18702 N. CREEK PARKWAY, BOTHELL

Employee

Twitter

Next Earnings Date

2024-11-07

Latest SEC Filings

IMNM's Discussions on Twitter

Immunome Inc Stock (IMNM) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
May-31-24	Initiated	Piper Sandler	Overweight
Apr-30-24	Initiated	JP Morgan	Overweight
Apr-15-24	Initiated	Guggenheim	Buy
Jan-29-24	Initiated	Leerink Partners	Outperform
Dec-19-23	Initiated	Wedbush	Outperform
Oct-29-21	Initiated	Cantor Fitzgerald	Overweight

View All

Immunome Inc Stock (IMNM) Latest News

08:00 AM

Immunome to Present at Guggenheim’s Inaugural Healthcare Innovation Conference - Business Wire

08:00 AM

02:29 AM

Vanguard Group Inc's Strategic Acquisition of Immunome Inc Shares - GuruFocus.com

02:29 AM

Nov 04, 2024

Immunome (NASDAQ:IMNM) Trading Up 8.7%Here's What Happened - MarketBeat

Nov 04, 2024

Nov 02, 2024

Learn to Evaluate (IMNM) using the Charts - Stock Traders Daily

Nov 02, 2024

Nov 01, 2024

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - StockTitan

Nov 01, 2024

Immunome, Inc. (NASDAQ:IMNM) Receives $29.00 Average PT from Brokerages - MarketBeat

Nov 01, 2024

Immunome, Inc. (NASDAQ:IMNM) Given Consensus Rating of “Buy” by Analysts - Defense World

Nov 01, 2024

Oct 31, 2024

Immunome (NASDAQ: IMNM) Acquires Zentalis Pharmaceuticals’ Licensed Assets IMMUNOME, Inc. made a recent significant move on October 25, 2024, by acquiring Zentalis Pharmaceuticals, Inc.’s Licensed Assets. This acquisition was carried out thr - Defense World

Oct 31, 2024

Oct 30, 2024

Immunome Advances with Strategic Asset Acquisition and Agreement - Yahoo Finance

Oct 30, 2024

Oct 29, 2024

Immunome Presents Compelling Preclinical Data Demonstrating Robust Anti-Tumor Activity for IM-1021 - Business Wire

Oct 29, 2024

Immunome, Inc. (NASDAQ:IMNM) Short Interest Down 15.2% in October - MarketBeat

Oct 29, 2024

Oct 25, 2024

Immunome's (IMNM) Outperform Rating Reiterated at Wedbush - MarketBeat

Oct 25, 2024

Oct 18, 2024

Immunome to Present Poster Highlighting Preclinical Evaluation of IM-1021, a ROR1-Targeted Antibody Drug Conjugate, at the 36th EORTC-NCI-AACR Symposium - The Bakersfield Californian

Oct 18, 2024

IMNMImmunome, Inc. Latest Stock News & Market Updates - StockTitan

Oct 18, 2024

Oct 15, 2024

Immunome (IMNM) Price Target Increased by 179.17% to 34.17 - MSN

Oct 15, 2024

Cubist Systematic Strategies LLC Reduces Stake in Immunome, Inc. (NASDAQ:IMNM) - Defense World

Oct 15, 2024

Cubist Systematic Strategies LLC Decreases Position in Immunome, Inc. (NASDAQ:IMNM) - MarketBeat

Oct 15, 2024

Oct 14, 2024

Understanding the Risks of Investing in Immunome Inc (IMNM) - Knox Daily

Oct 14, 2024

Financial Metrics Exploration: Understanding Immunome Inc (IMNM) Through Ratios - The Dwinnex

Oct 14, 2024

Oct 12, 2024

Sei Investments Co. Cuts Position in Immunome, Inc. (NASDAQ:IMNM) - Defense World

Oct 12, 2024

Oct 11, 2024

(IMNM) Investment Analysis and Advice - Stock Traders Daily

Oct 11, 2024

Oct 10, 2024

Insider Selling: Rosett Max, Immunome Inc [IMNM] Chief Financial Officer divested 14,380 shares - Knox Daily

Oct 10, 2024

Did Immunome Inc (IMNM) perform well in the last session? - US Post News

Oct 10, 2024

The Manufacturers Life Insurance Company Has $2.02 Million Holdings in Immunome, Inc. (NASDAQ:IMNM) - MarketBeat

Oct 10, 2024

Oct 09, 2024

Immunome (NASDAQ:IMNM) Shares Down 6.1%Here's Why - MarketBeat

Oct 09, 2024

Oct 08, 2024

Immunome Inc. launches new inducement plan By Investing.com - Investing.com South Africa

Oct 08, 2024

Immunome names Roee Shahar as EVP, Commercial By Investing.com - Investing.com South Africa

Oct 08, 2024

Immunome Appoints Roee Shahar as Executive Vice President, Commercial - BioSpace

Oct 08, 2024

Immunome names Roee Shahar as EVP, Commercial - Investing.com

Oct 08, 2024

Oct 07, 2024